Not sure that has been established. CC3D has been on the market a while and we have not seen a substantial boost in revenue or gross profit.
Perhaps volumes are still too low to have much impact, but we were led to believe there was plenty of pent up demand (this was supposed to be our halo effect product).
If Cardiocel is truely unique, we should not be having the same issues with competition as with the flat patch. If so, where is the sales spike!?
Would love to see a detailed sales breakdown by product/region
Ann: Appendix 4D and Half Yearly Financial Report, page-198
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.60 |
Change
-0.100(0.53%) |
Mkt cap ! $357.5M | |||
| Open | High | Low | Value | Volume |
| $18.70 | $18.77 | $18.21 | $664.1K | 35.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $18.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.69 | 53 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |